Trius Therapeutics Inc (TSRX) [Rocket]

In millions, except per share items	Dec-31-12	Dec-31-11	Dec-31-10	Dec-31-09	Dec-31-08
	10-K	10-K	10-K	10-K	10-K
Revenues	27.2	41.0	8.0	5.0	1.3
Revenue growth	-33.7%	410.6%	60.1%	277.1%
Cost of goods sold	0.0	0.0	0.0	0.0	2.3
Gross profit	27.2	41.0	8.0	5.0	-1.0
Gross margin	100.0%	100.0%	100.0%	100.0%	-72.2%
Selling, general and administrative [+]	15.4	11.3	5.4	4.1	2.3
General and administrative	15.4	11.3	5.4	4.1	2.3
Research and development	69.0	49.5	23.3	23.0
Other operating expenses					17.8
EBITDA [+]	-56.6	-19.3	-20.3	-21.5	-20.5
EBITDA growth	192.6%	-4.8%	-5.4%	4.7%
EBITDA margin	-208.1%	-47.1%	-252.8%	-428.1%	-1541.5%
Depreciation and amortization	0.7	0.5	0.4	0.7	0.5
EBIT [+]	-57.2	-19.8	-20.7	-22.2	-21.0
EBIT growth	188.6%	-4.2%	-6.6%	5.3%
EBIT margin	-210.5%	-48.4%	-257.6%	-441.9%	-1582.4%
Interest expense, net [+]	0.0	0.0	3.9	0.2	-0.3
Interest expense			3.9	0.3	0.3
Interest income	0.0	0.0	0.0	0.0	0.6
Other income (expense), net [+]	3.3	1.6	0.7	-0.3	0.0
Other	0.0	0.0	0.2	0.0
Pre-tax income	-53.9	-18.3	-23.9	-22.7	-20.8
Income taxes	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-53.9	-18.3	-23.9	-22.7	0.0
Net margin	-198.4%	-44.5%	-297.3%	-452.7%	-1.6%

Basic EPS [+]	($1.42)	($0.69)	($2.36)	($31.11)	($40.19)
Growth	105.8%	-70.9%	-92.4%	-22.6%
Diluted EPS [+]	($1.42)	($0.69)	($2.36)	($31.11)	($40.19)
Growth	105.8%	-70.9%	-92.4%	-22.6%

Shares outstanding (basic) [+]	38.1	26.5	10.1	0.7	0.0
Growth	43.6%	162.6%	1283.4%	140826.6%
Shares outstanding (diluted) [+]	38.1	26.5	10.1	0.7	0.0
Growth	43.6%	162.6%	1283.4%	140826.6%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.